lapatinib has been researched along with doxazosin in 2 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (doxazosin) | Trials (doxazosin) | Recent Studies (post-2010) (doxazosin) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 1,372 | 439 | 283 |
| Protein | Taxonomy | lapatinib (IC50) | doxazosin (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.544 | |
| Interstitial collagenase | Homo sapiens (human) | 5.749 | |
| Beta-2 adrenergic receptor | Homo sapiens (human) | 2.748 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 2.2155 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.0034 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.544 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 2.688 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.368 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0007 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.188 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.4022 | |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | 2.2155 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Battastini, AM; Coelho, BP; de Quadros, AH; Gaelzer, MM; Gonçalves, CA; Guerra, MC; Guma, FC; Hoppe, JB; Salbego, CG; Setton-Avruj, P; Terra, SR; Usach, V | 1 |
1 review(s) available for lapatinib and doxazosin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for lapatinib and doxazosin
| Article | Year |
|---|---|
Phosphatidylinositol 3-Kinase/AKT Pathway Inhibition by Doxazosin Promotes Glioblastoma Cells Death, Upregulation of p53 and Triggers Low Neurotoxicity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Chromones; Doxazosin; Enzyme Activation; G1 Phase Cell Cycle Checkpoints; Glioblastoma; Glycogen Synthase Kinase 3 beta; Hippocampus; Humans; Lapatinib; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Rats, Wistar; Tumor Suppressor Protein p53 | 2016 |